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This review highlights the role of vitamins and natural compounds in breast cancer prevention,
with a particular focus on Vitamin D. In the last decades, both encouraging and discouraging results
about the association between antioxidant supplementation and cancer have been reported to
public and scientific community. Their safe and favorable toxicity profile makes them suitable to be
investigated in a preventive setting. However, a recent large meta-analysis showed that treatment
with beta carotene, vitamin A, and vitamin E may increase mortality, whereas the potential roles of
vitamin C and selenium on mortality need further study. Likewise, folate levels were not associated
with reduced breast cancer risk in a recent meta-analysis. Several studies have shown that a high
proportion of women at-risk for breast cancer or affected by the disease have deficient vitamin D
levels, i.e., 25OH-D <20ng/ml or 50nmol/L. While the association between Vitamin D levels and
breast cancer risk/prognosis is still controversial, the U-shaped relationship between 25OH-D levels
observed in different studies suggests the need to avoid both deficient and too high levels. Further
trials using an optimal dose range are needed to assess the preventive and therapeutic effect of
vitamin D. Finally, Fenretinide, a pro-apoptotic and pro-oxidant vitamin A derivative, has shown
promise in several trials and its preventive potential is being assessed in young women at very
high risk for breast cancer.
© 2011 Elsevier Ltd. All rights reserved.
Antioxidants and risk of mortality
Oxidative stress is strongly implicated in most human diseases,
including cancer.1 Observational studies found positive associations
between antioxidants and improved health.2–5 Recently, also
because of exposed to intense marketing, many people are taking
antioxidant supplements, believing to improve their health and
prevent diseases6–9 and many primary or secondary prevention
trials of antioxidant supplements have been conducted to prevent
several diseases.
Bjelakovic et al. found that antioxidant supplements, with the
potential exception of selenium, were without significant effects
on gastrointestinal cancers and increased all-cause mortality.10,11
In a recent review12 the same authors published a remarkable
systematic review assessing the effects of antioxidant supplements
on all-cause mortality of adults included in randomized primary
and secondary prevention trials.
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All trials were conducted in adults randomized to receive beta
carotene, vitamin A, vitamin C, vitamin E, or selenium vs. placebo
or no intervention; the antioxidants were administered singly, in
combination with other antioxidants, or with other vitamins or
trace elements.
Analyses were stratified according to the risk of bias: trials with
adequate randomization, blinding, and follow-up procedures were
considered low-bias risk trials (high methodological quality), as
well as trials with ≥1 unclear or inadequate quality components
were classified as high-bias risk trials (low methodological quality).
Meta-regression was used to assess the effect of covariates across
the trials.
Forty-seven of the 68 trials (69.1%) had low-bias risk. The
remaining trials had one or more inadequate components. A
total of 232.606 participants were included, for a total of
68 trials, 385 publications. The primary prevention trials were 21;
secondary prevention trials were 47 including 68167 participants
mainly with gastrointestinal, cardiovascular, neurological, ocular
and dermatological diseases.
In the primary prevention trials the main outcomemeasures were
cancer incidence and mortality (cause specific and all cause); in the
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secondary prevention trials outcome measures were progression
of disease and mortality. All antioxidant supplements were
administered orally. Beta carotene was tested in 25 trials, vitamin A
in 16, vitamin C in 34, vitamin E in 55, and selenium in 21.
The pooled effect of all supplements vs. placebo or no
intervention in all randomized trials was not significant (RR, 1.02;
95%CI, 0.98–1.06). In multivariate meta-regression only two
covariates were significantly associated with mortality: dose of
selenium (RR, 0.998; 95%CI, 0.997–0.999; P = 0.005) and low-
bias risk trials (RR, 1.16; 1.05–1.29; P = 0.005). Risk mortality was
significantly increased in the supplemented group in low-bias
risk trials (RR, 1.05; 95%CI, 1.02–1.08), while was significantly
decreased in high-bias risk trials (RR, 0.91; 95%CI, 0.83–1.00,
p for interaction =0004). When single agents were considered,
beta carotene, vitamin A and E, were significantly associated with
increased mortality, especially after exclusion of high-bias trials and
selenium trials. Vitamin C given singly or in combination was not
significantly associated to risk mortality, even after the exclusion of
high-bias risk trials and selenium trials. Selenium, after exclusion
of high-bias risk trials, given singly or with other antioxidants had
no significant influence on mortality.
Authors discussed possible explanations for the null/negative
effect of antioxidant supplements on mortality, with the evidence
that oxidative stress may also be the consequence of pathological
conditions13 and, by eliminating free radicals from our organism,
we interfere with some beneficial defensive mechanisms (i.e.
apoptosis, phagocytosis, detoxification).14–16 Moreover, antioxidant
supplements are synthetic and not subjected to the same
rigorous toxicity studies as other pharmaceutical agents.17 Better
understanding of mechanisms and actions of antioxidants in
relation to a potential disease is needed.18
Folate and breast cancer risk
Evidence from observational case control studies suggests that
increasing dietary folate intake is associated with a reduced risk
of breast cancer but large cohort studies have not found any
association, and animal studies suggest that folate supplementation
may promote tumorigenesis.
A meta-analysis was recently published by Lewis SJ et al.19
to summarize the available evidence from observational studies
on this issue but also on the association between a common
polymorphism in a key enzyme in folate metabolism (5,10-
methylenetetrahydrofolate reductase [MTHFR] gene), and breast
cancer risk. A total of 26 studies (14 case-control and 12 cohort
studies) were identified.
A statistically significant association between folate levels and
breast cancer risk (OR=0.91, 95%CI = 0.87 to 0.96) was found
for the 13 case–control studies, while on the 9 cohort studies
that measured folate intake rather than biomarkers of folate the
association was not statistically significant (RR=0.99, 95%CI = 0.98
to 1.01, for a 100mg/d increase in folate intake). When the analysis
was restricted to premenopausal breast cancer, the association was
significant only for case-control studies (OR=0.87, 95%CI = 0.78 to
0.97) even if publication bias was statistically significant (small
study effect overestimated the summary estimate).
The meta-analysis of the MTHFR C677T polymorphism and breast
cancer risk included a total of of 17 studies, 6373 case and 8434
control subjects. The summary odds ratio for TT homozygotes
versus CC homozygotes was 1.04 (95%CI = 0.94 to 1.16). In addition,
we found that the summary odds ratio for heterozygotes versus
TT and CC homozygotes considered together was 1.01 (95%CI =
0.94 to 1.08).
Authors concluded with a substantial no consistent or reliable
evidence to support a role of dietary folate in breast cancer
prevention, especially from the cohort studies, whereas the case-
control studies showed a risk reduction associated with dietary
folate intake, but in this case the risk of chance, bias, measurement
error, and/or confounding may be high. No evidence of an
association between the MTHFR C677T polymorphism and breast
cancer risk was found.
Biological effects of vitamin D
Calcitriol (1,25-dihydroxyvitamin D [1,25(OH)D]), the hormonal
derivative of vitamin D, has been established since the 1980s as an
antiproliferative and prodifferentiation agent, and as a proapoptotic
agent and an inhibitor of cell migration, which may imply an
inhibitory effect on cancer.20 Vitamin D is indeed more like a
hormone and not strictly a vitamin according to the classical criteria
that an essential nutrient is a substance the body cannot synthesise
in sufficient quantities itself. Also, vitamins are usually involved in
biochemical reactions, while 1a,25-dihydroxyvitamin D exerts its
action via VDR.
Vitamin D represents a group of fat-soluble prohormones, the
two major forms of which are vitamin D2 (or ergocalciferol) and
vitamin D3 (or cholecalciferol). Endogenous synthesis of vitamin D3
takes place in the skin under the influence of ultra violet B (UVB)
radiation. Exogenous vitamin D2 or D3 comes from dietary intake.
The overall vitamin D intake is the sum of cutaneous vitamin D and
nutritional vitamin D.
Vitamin D on its own has no physiological action. To be
physiologically active, vitamin D must first be hydroxylated in the
liver by the enzyme 25-hydroxylase, encoded by CYP27A1 (also
called the 25-hydroxylase or 25(OH)D), into 25-hydroxyvitamin D.
The 25-hydroxyvitamin D is inactive, and an additional hydroxy-
lation in the kidney by the enzyme 1a-hydroxylase, encoded by
CYP27B1 (also called 41a-hydroxylase), is necessary to produce the
physiologically active vitamin D metabolite, calcitriol or 1,25(OH)D.
When 1,25(OH)D is sufficiently available, the enzyme mitochondrial
protein encoded by CYP24A1 metabolises the 1,25(OH)D into
1a,24,25-dihydroxyvitamin D, which is further catabolised to
calcitroic acid. 25(OH)D and 1,25(OH)D are transported in serum
by the vitamin D-binding protein (GC).
Optimal serum levels of 25(OH)D
In general, modern society is vitamin D-deprived compared with
prehistoric humans. Hundreds of thousands of years ago, our
remote ancestors lived mostly in the tropics and were exposed
to strong sunlight year-round. According to researchers, vitamin D
deficiency didn’t appear to be a problem. As people migrated away
from the equator, they got less sun. “Civilization” and urbanization
made the deficiency much worse, and vitamin D deficiency reached
a peak in the 18th and 19th centuries when people began moving in
droves from rural areas to cities, where tall buildings blocked the
sunlight. Dark-skinned people who migrate northward from low,
tropical latitudes produce less vitamin D, which can adversely affect
the immune system as well as the skeleton. Further factors include
the increase in urbanization, where people tend to live and work in-
doors, as well as cultural practices that tend towards sun avoidance
and the wearing of traditional clothing that covers the skin.
In fact most of vitamin D supply is provided through endogenous
synthesis of vitamin D3 upon sunshine exposure and will depend on
amounts of UVB reaching earth surface, on skin surface exposed to UVB
and on skin pigmentation.
Only a few foods naturally contain appreciable amounts of
vitamin D to have an impact either through the form of
cholecalciferol (vitamin D3) derived from animal sources, or
ergocalciferol (vitamin D2), from plant food. The concentrations of
25(OH)D observed today are based on contemporary cultural norms
(clothing, sun avoidance, food choices and legislation).
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Vitamin D and mortality from all causes
A meta-analysis of published randomised trials s showed a
significant reduction of 7% in total mortality (RR 0.93, p < 0.05) in
healthy subjects taking vitamin D. No indication of hetergeneity
nor publication bias was found. Eighty-two percent of patients
received vitamin D3 (cholecalciferol), the remaining vitamin D2
(ergocalciferol), either orally or by injection. Average daily doses
ranged from 300 IU to 2,000 IU. Treatment ranged from daily to
4-monthly, and follow-up ranged from 6 months to 7 years.21
The Netherlands Longitudinal Aging Study examined, during a
6-year follow-up, the risk of death of 1,260 community dwelling
people 65 years old or more according to serum 25(OH)D levels
measured at baseline.22 The results indicated that subjects with
serum 25(OH)D levels lower than 20ng/mL had a mortality risk
associated with steadily lower levels (p < 0.0001).
In the Third National Health and Nutrition Examination Survey
(NHANES III, USA) 13,331 adults, 20 years or older, were followed
for a median of 8.7 years.23 There were 1,806 deaths, 777 from
cardiovascular disease (CVD) and 424 from cancer. Serum 25(OH)D
levels below 17.8 ng/mL were associated with a 26% increased rate
of all-cause mortality (95%CI: +8%; +46%). However U-shaped risk
curves was also pointed out with a possible increased risk when
levels are above 32.1 ng/ml.
The U-shaped association was also found in two cohort studies
between 25-hydroxyvitamin D levels and colorectal or prostate
cancer risk.24,25 Furthermore the Framingham Offspring Study
suggest that low as well as high 25-hydroxyvitamin D could be
associated with increased incidence of cardiovascular diseases.26
These trends could be considered as isolated observations
because upper quartiles of 25-hydroxyvitamin D levels were not
higher than in other studies and the statistical power to investigate
the risk at very high level is very low. However, these results may
also mean that, like for many agents that were proposed for cancer
chemoprevention, a high vitamin D status could be associated with
an increased risk of cancer or other serious adverse event. If real,
this type of dose–effect relationship would mean that increasing
25-hydroxyvitamin D could bring health benefits among subjects
with low vitamin D status, while it could lead to increased risks in
subjects who have a high or a very high vitamin D status before
starting to take supplements.
Evidence from Vitamin D trials
The Women’s Health Initiative (WHI) in the USA27 randomized
36,282 postmenopausal women to 400 IU of vitamin D per day
and 1g of elementary calcium, or to placebo.27,28 After a mean
of 7 years’ follow-up the intervention did not alter the risk of
colorectal and breast cancers, or of all cancers. The negative findings
of theWHI trial have been attributed to inadequate vitamin D doses,
too low adherence to supplementation, too short a trial duration, or
interactions between vitamin D and other substances, for example,
menopausal hormone replacement therapy and calcium.29,30
Nonetheless, the discrepancy between observational and ran-
domized trials points to the alternative hypothesis that vitamin D
status would reflect an individual’s propensity to develop colorectal
cancer rather than be the cause of that cancer. This propensity
would be associated with lifestyle, e.g., obesity, smoking, low
physical activity and other unknown risk factors that cannot be
controlled by statistical analysis.
Vitamin D and cancer risk
Results from the meta-analyses on 25(OH)D serum levels and
cancer incidence, within the working group of experts, organized by
the International Agency for Cancer Research, showed a significant
reduction in risk for colorectal cancer comparing the highest levels
versus the lowest level of 25(OH)D, with a significant dose-response
effect.31,32
For breast cancer, the pooled estimates of 0.89 reached statistical
significance. However, restricting the analysis to prospective studies
(3,145 cases) yielded a SRR of 0.97 for a 10ng/ml increase (95%CI:
0.92–1.03), whereas the SSR for the five case-control studies
(3,030 cases) was 0.83 (95%CI: 0.79–0.87) (p< 0.001 for the differ-
ence between SRRs). These results suggest that the five case-control
studies were responsible for the apparent decrease in breast cancer
risk associated with increasing serum 25-hydroxyvitamin D level.
The case-control design implies that the measurement of
25-hydroxyvitamin D is done in individuals already diagnosed
with cancer. Therefore, results from this study design need to
be interpreted cautiously because of the potential for reverse
causation, that is, low vitamin D status being a consequence, rather
than a cause of the disease. For example, when symptoms are severe
or during the treatment of cancer, exposure to sunlight and dietary
habits are likely to change (due to hospitalizations, disability or
change in lifestyle).
The “nested case-control” study is a case-control study embedded
within a prospective cohort study, and serum 25-hydroxyvitamin D
level is measured in archived blood samples collected several
years before disease diagnosis. Therefore, in cohort and nested-
case-control studies, as the blood sample is taken well before the
diagnosis of cancer, it is unlikely that any association observed
is due to the effect of cancer on the blood level of 25-
hydroxyvitamin D.
Among the studies included, the lowest values of 25(OH)D for the
upper categories in average were 34mg/ml and the upper levels of
the lowest category was 18mg/ml.31 Inadequate levels of circulating
25(OH)D are associated also with an increased risk and poor.
A recent study on prognostic effects of circulating 25(OH)D in
a cohort of patients with early breast cancer found that deficient
levels of vitamin D were associated with higher-grade tumors
suggesting that the prognostic effect of vitamin D may be due,
in part, to the development of higher-grade tumors in vitamin D-
deficient women, consistent with a potential role of vitamin D in
breast carcinogenesis.33
Clinical suggestions
Current efforts to assess optimal serum concentrations of 25(OH)D
generally focus on bone health in older white persons, and the
common definition of the optimal level has been the concentration
that maximally suppresses serum parathyroid hormone (PTH).
In most persons, the optimal level cannot be reached with the
currently recommended intake is 200 IU and 600 IU/d for younger
and older adults respectively. The total 25(OH)D serum levels, i.e.
25(OH)D2 plus 25(OH)D3, is what physicians need to be aware of in
their patients.
Vitamin D deficiency is defined by most experts as a 25(OH)D
level of less than 20ng/ml (50 nmol per liter).34–37 By these
standards both the European and US populations are vitamin D
insufficient or deficient.
The synthetic retinoic acid derivative fenretinide
Retinoids are natural and synthetic analogues of vitamin A. They are
known to play a crucial role in cellular and tissue differentiation,
because of their capability to activate and/or repress specific genes
and consequently to suppress tumor promotion and modify some
properties of fully transformed malignant cells.38 Retinamides are
synthetic retinoids which have been modified to extend target
organ specificity, increase anticarcinogenic activity, and reduce
toxicity.39
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Fenretinide is the synthetic amide of retinoic acid N-(4-hydroxy-
phenyl)retinamide (4-HPR) and it was synthesized in the late 1960s.
The studies on fenretinide biological activity immediately showed
the preferential accumulation of this drug in the breast instead of
the liver,40 the higher activity and lower toxicity when compared
to other retinoids.41 In animal model Fenretinide demonstrated to
suppress the recurrence of mammary cancer after primary tumor
removal42 and to inhibit the progression of ductal hyperplastic
lesions and ductal carcinoma in situ.43
The mechanism of action of fenretinide is not yet completely
known but it has been shown that it might exert its inhibitory
effects by both receptor dependent and independent mecha-
nisms.44–46 The binding of retinoids to the nuclear receptors (i.e.,
retinoic acid receptor (RAR)-alfa, -beta and -gamma and retinoid
X receptor (RXR)-alfa, -beta and -gamma), which are ligand-
activated transcription factors, leads to the regulation of several
cellular processes, including growth, differentiation and apoptosis.47
Furthermore, fenretinide inhibits also the proliferation of breast
cancer cells that do not express retinoic acid receptors (RARs) and
more recent data demonstrated that fenretinide has a very poor
affinity to this receptor class.44 Fenretinide is responsible of both the
increasing of RAR-beta expression and the decreasing of cell cycle
modulators in different cancer cell lines including breast cancer
cells, such as cyclins D and cyclin-dependent kinases.48–50
A unique feature of fenretinide is the ability to inhibit cell
growth proliferation through the induction of apoptosis rather than
differentiation (Fig. 1), a specific effect which is completely different
from that of all-trans retinoic acid.51,52 Fenretinide mediated
apoptosis seems to be tissue specific and multiple mechanisms
might operate within specific tissues.47 Generation of reactive
oxygen species (ROS) such as hydrogen peroxide and superoxide
seems to be critical in mediating apoptosis in different cancer cell
types.53–55 Mechanisms specific to fenretinide as compared with
other retinoids are the production of nitric oxide (NO) by nitric
oxide synthases (NOS)56,57 and sphingolipid ceramide elevation
in level.58 These mechanisms may be interrelated and, in breast
cancer cells, it has been shown that NO-mediated induction of
apoptosis requires mitochondrial damage, including cytochrome-c
release, disruption of mitochondrial transmembrane potential and
ROS generation, as well as activation of caspases.59 If we were to
Fig. 1. Signaling pathways proposed for fenretinide-induced apoptosis. Abbrevia-
tions: RARs, retinoic acid receptors; RXRs, retinoic X receptors; ROS, reactive oxygen
species.
take a reductionist approach, ROS production and mitochondrial
membrane permeabilization could reasonably be predicted to be
involved, at least in part, in apoptosis induction by fenretinide in
most cell systems.60
The over fifteen-year follow up of a randomized phase III
trial61 of fenretinide to prevent second breast cancer indicates
that fenretinide induced an overall 17%, durable reduction of
second breast cancer incidence. More important when stratified
by menopausal status, the analysis showed a 38%, statistically
significant reduction of second breast cancers in premenopausal
women and this protective effect persisted for up to 15 years,
i.e. 10 years after treatment cessation. Importantly, the younger
were the women, the greater was the trend of benefit of
fenretinide, with a remarkable 50% risk reduction in women
aged 40 years or younger, whereas the benefit disappeared after
age 55. One explanation for the different effects of fenretinide
according to menopausal status or age is a different modulation
of circulating IGF-I in premenopausal and postmenopausal women,
with a reduction of IGF-I levels only in premenopausal subjects.
Additional fenretinide mechanisms have been investigated, such
as the capability of retinoids to inhibit cell growth by reducing
the expression of growth-stimulating factors or by inducing
the expression of growth-inhibitory factors. In vitro, fenretinide
is correlated both with a decreased secretion of insulin-like
growth factor-I (IGF-I), a stimulator of epithelial cell growth,
and an increased secretion of IGF-binding proteins (IGFBPs).62,63
Higher circulating insulin-like growth factor-I levels are associated
with greater risk of developing subsequent breast cancer in
premenopausal women64 and Fenretinide has shown to be able
to decrease plasma IGF-1 levels.65,66 During intervention we also
observed 6 cases of ovarian cancer in the control arm vs 0 in the
treated arm. At 15 years follow up, 10 cases in the control group
and 6 in the fenretinide group. These results are not statistically
significant but these data need to be further investigated. When
considering the protective activity of fenretinide on second breast
cancer in young women and a similar trend on ovarian cancer (the
latter at least during intervention), it appears that young women
at high risk such as those with germline BRCA-1 and BRCA-2
mutations or those with a high family risk may be ideal candidates
for further investigation on this retinoid. Moreover, fenretinide is
highly effective in inhibiting the growth of BRCA-1 mutated breast
cancer cell lines.67 Additionally, recent studies have shown that
4-HPR modulates gene expression in ovarian cells, with an up-
regulation of expression of proapoptotic genes in OVCA433 cells
and down-regulation of mutant BRCA genes in IOSE (premalignant)
cells and OVCA433 cells.68
The prolonged effect demonstrated in the first phase III
chemopreventive trial in breast cancer subjects, together with a
trend of protective effect on the ovaries, has been accompanied by a
very low toxicity profile (mainly reversible skin dryness and rashes
and dark adaptation difficulties, often overcome by a monthly
weekend suspension of the drug). Like other retinoids, fenretinide
may be potentially teratogenic, although available studies show
no genotoxic effects in vitro and limited effects in vivo, and a
lack of storage in the human embryo. Thus, appropriate measures
of contraception will be adopted when treating potentially fertile
women.
Since a reduction of second breast cancer might be a surrogate
marker of primary prevention, a favourable effect of fenretinide in
premenopausal women provides a strong rationale for a primary
prevention trial in unaffected women at high risk of breast cancer.69
If we consider the protective activity of fenretinide on second
breast cancer in young women and a similar trend on ovarian
cancer, at least during intervention, it appears that women with
germline BRCA 1 and 2 mutations may be ideal candidates for
further investigation of this retinoid.
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Key findings
Treatment with beta carotene, vitamin A, and vitamin E may increase mortality.
The potential roles of vitamin C and selenium on mortality need further study.
• By eliminating free radicals, we interfere with some essential defensive mechanisms of oxidative stress like apoptosis, phagocytosis,
and detoxification.
• Antioxidant supplements are synthetic and not subjected to the same rigorous toxicity studies as other pharmaceutical agents.
• Because we examined only the influence of synthetic antioxidants, these findings should not be translated to potential effects of
fruits and vegetables.
A high proportion of women at-risk for breast cancer or affected have deficient vit D levels, i.e., 25OH-D <20ng/ml or 50nmol/L
• Vitamin D levels and breast cancer risk/prognosis: evidence still controversial.
• U-shaped relationship between 25OH-D levels and disease (avoid deficient and too high levels).
• Importance of attaining adequate levels, i.e, 30–40ng/ml (e.g., 100000 IU q2 months or 10000 IU q week).
• Further trials with optimal dose range are needed to assess the preventive and therapeutic effect of vitamin D.
Fenretinide is a retinoic acid derivative which inhibits cell growth proliferation through the induction of apoptosis rather than
differentiation.
• Fenretinide might exert its inhibitory effects by both receptor dependent and independent mechanisms.
• In a phase III breast cancer prevention trial, fenretinide showed a significant reduction of second breast malignancies in
premenopausal women and a promising trend on ovarian cancer during intervention. A phase III trial is underway in young
women at very high risk for breast cancer.
Conflict of interest statement
The authors have no conflict of interest to declare.
References
1. Halliwell B. Free radicals and antioxidants – quo vadis? Trends Pharmacol Sci
2011;32:125–30.
2. Machlin LJ, Bendich A. Free radical tissue damage: protective role of antioxidant
nutrients. FASEB J 1987;1:441–5.
3. Diplock AT. Antioxidants and disease prevention. Mol Aspects Med 1994;15:293–
376.
4. van PG, van den BH. Vitamins and cancer. Cancer Lett 1997;114:195–202.
5. Diplock AT, Charleux JL, Crozier-Willi G, et al. Functional food science and
defence against reactive oxidative species. Br J Nutr 1998;80(Suppl 1):S77–112.
6. Balluz LS, Kieszak SM, Philen RM, Mulinare J. Vitamin and mineral supplement
use in the United States. Results from the third National Health and Nutrition
Examination Survey. Arch Fam Med 2000;9:258–62.
7. Radimer K, Bindewald B, Hughes J, et al. Dietary supplement use by US adults:
data from the National Health and Nutrition Examination Survey, 1999–2000.
Am J Epidemiol 2004;160:339–49.
8. Millen AE, Dodd KW, Subar AF. Use of vitamin, mineral, nonvitamin, and
nonmineral supplements in the United States: The 1987, 1992, and 2000
National Health Interview Survey results. J Am Diet Assoc 2004;104:942–50.
9. Nichter M, Thompson JJ. For my wellness, not just my illness: North Americans’
use of dietary supplements. Cult Med Psychiatry 2006;30:175–222.
10. Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Antioxidant supple-
ments for preventing gastrointestinal cancers. Cochrane Database Syst Rev
2008;CD004183.
11. Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Antioxidant supplements for
prevention of gastrointestinal cancers: a systematic review and meta-analysis.
Lancet 2004;364:1219–28.
12. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in
randomized trials of antioxidant supplements for primary and secondary
prevention: systematic review and meta-analysis. JAMA 2007;297:842–57.
13. Halliwell B. Free radicals, antioxidants, and human disease: curiosity, cause, or
consequence? Lancet 1994;344:721–4.
14. Salganik RI. The benefits and hazards of antioxidants: controlling apoptosis and
other protective mechanisms in cancer patients and the human population. J Am
Coll Nutr 2001;20:464S–472S.
15. Simon HU, Haj-Yehia A, Levi-Schaffer F. Role of reactive oxygen species (ROS) in
apoptosis induction. Apoptosis 2000;5:415–8.
16. Kimura H, Sawada T, Oshima S, et al. Toxicity and roles of reactive oxygen species.
Curr Drug Targets Inflamm Allergy 2005;4:489–95.
17. Bast A, Haenen GRMM. The toxicity of antioxidants and their metabolites.
Environmental Toxicology and Pharmacology 2002;11:251–8.
18. Ratnam DV, Ankola DD, Bhardwaj V, Sahana DK, Kumar MN. Role of antioxidants
in prophylaxis and therapy: A pharmaceutical perspective. J Control Release
2006;113:189–207.
19. Lewis SJ, Harbord RM, Harris R, Smith GD. Meta-analyses of observational and
genetic association studies of folate intakes or levels and breast cancer risk.
J Natl Cancer Inst 2006;98:1607–22.
20. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer:
potential for anticancer therapeutics. Nat Rev Cancer 2007;7:684–700.
21. Autier P, Gandini S. Vitamin D supplementation and total mortality: a meta-
analysis of randomized controlled trials. Arch Intern Med 2007;167:1730–7.
22. Visser M, Deeg DJ, Puts MT, Seidell JC, Lips P. Low serum concentrations of 25-
hydroxyvitamin D in older persons and the risk of nursing home admission. Am
J Clin Nutr 2006;84:616–22.
23. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the
risk of mortality in the general population. Arch Intern Med 2008;168:1629–37.
24. Garland CF, Comstock GW, Garland FC, et al. Serum 25-hydroxyvitamin D and
colon cancer: eight-year prospective study. Lancet 1989;2:1176–8.
25. Tuohimaa P, Tenkanen L, Ahonen M, et al. Both high and low levels of blood
vitamin D are associated with a higher prostate cancer risk: a longitudinal,
nested case-control study in the Nordic countries. Int J Cancer 2004;108:104–8.
26. Wang AY, Lam CW, Sanderson JE, et al. Serum 25-hydroxyvitamin D status
and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y
prospective cohort study. Am J Clin Nutr 2008;87:1631–8.
27. Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D
supplementation and the risk of colorectal cancer. N Engl J Med 2006;354:
684–96.
28. Chlebowski RT, Johnson KC, Kooperberg C, et al. Calcium plus vitamin D
supplementation and the risk of breast cancer. J Natl Cancer Inst 2008;100:
1581–91.
29. Holick MF. Calcium plus vitamin D and the risk of colorectal cancer. N Engl J
Med 2006;354:2287–8.
30. Giovannucci E. Calcium plus vitamin D and the risk of colorectal cancer. N Engl
J Med 2006;354:2287–8.
31. IARC Working Group. Vitamin D and Cancer. 2008.
32. Gandini S, Boniol M, Haukka J, et al. Meta-analysis of observational studies of
serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer
and colorectal adenoma. Int J Cancer 2011;128:1414–24.
33. Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N. Prognostic effects of 25-
hydroxyvitamin D levels in early breast cancer. J Clin Oncol 2009;27:3757–63.
34. Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health
consequences. Am J Clin Nutr 2008;87:1080S–1086S.
35. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266–81.
36. Gorham ED, Garland CF, Garland FC, et al. Vitamin D and prevention of colorectal
cancer. J Steroid Biochem Mol Biol 2005;97:179–94.
37. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, wson-Hughes B.
Estimation of optimal serum concentrations of 25-hydroxyvitamin D for
multiple health outcomes. Am J Clin Nutr 2006;84:18–28.
M. Lazzeroni et al. / The Breast 20 (2011) S36–S41 S41
38. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J
1996;10:940–54.
39. Cobleigh MA. Breast cancer and fenretinide, an analogue of vitamin A. Leukemia
1994;8(Suppl 3):S59-S63.
40. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical
carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc
1976;35:1332–8.
41. Mehta RG, Moon RC, Hawthorne M, Formelli F, Costa A. Distribution of
fenretinide in the mammary gland of breast cancer patients. Eur J Cancer
1991;27:138–41.
42. Moon RC, Pritchard JF, Mehta RG, et al. Suppression of rat mammary cancer
development by N-(4-hydroxyphenyl)retinamide (4-HPR) following surgical
removal of first palpable tumor. Carcinogenesis 1989;10:1645–9.
43. Green A, Shilkaitis A, Christov K. 4-(hydroxyphenyl)retinamide selectively
inhibits the development and progression of ductal hyperplastic lesions and
carcinoma in situ in mammary gland. Carcinogenesis 1999;20:1535–40.
44. Sheikh MS, Shao ZM, Li XS, et al. N-(4-hydroxyphenyl)retinamide (4-HPR)-
mediated biological actions involve retinoid receptor-independent pathways in
human breast carcinoma. Carcinogenesis 1995;16:2477–86.
45. Fanjul AN, Delia D, Pierotti MA, et al. 4-Hydroxyphenyl retinamide is a highly
selective activator of retinoid receptors. J Biol Chem 1996;271:22441–6.
46. Sun SY, Li W, Yue P, et al. Mediation of N-(4-hydoxyphenyl)retinamide-induced
apoptosis in human cancer cells by different mechanisms. Cancer Res 1999;59:
2493–8.
47. Simeone AM, Tari AM. How retinoids regulate breast cancer cell proliferation
and apoptosis. Cell Mol Life Sci 2004;61:1475–84.
48. Liu G, Wu M, Levi G, Ferrari N. Inhibition of cancer cell growth by all-
trans retinoic acid and its analog N-(4-hydroxyphenyl) retinamide: a possible
mechanism of action via regulation of retinoid receptors expression. Int J Cancer
1998;78:248–54.
49. Sabichi AL, Hendricks DT, Bober MA, Birrer MJ. Retinoic acid receptor beta
expression and growth inhibition of gynecologic cancer cells by the synthetic
retinoid N-(4-hydroxyphenyl) retinamide. J Natl Cancer Inst 1998;90:597–605.
50. Panigone S, Debernardi S, Taya Y, et al. pRb and Cdk regulation by
N-(4-hydroxyphenyl)retinamide. Oncogene 2000;19:4035–41.
51. Lotan R. Retinoids and apoptosis: implications for cancer chemoprevention and
therapy. J Natl Cancer Inst 1995;87:1655–7.
52. Wu JM, DiPietrantonio AM, Hsieh TC. Mechanism of fenretinide (4-HPR)-induced
cell death. Apoptosis 2001;6:377–88.
53. Delia D, Aiello A, Meroni L, et al. Role of antioxidants and intracellular free
radicals in retinamide-induced cell death. Carcinogenesis 1997;18:943–8.
54. Oridate N, Suzuki S, Higuchi M, et al. Involvement of reactive oxygen species in
N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells.
J Natl Cancer Inst 1997;89:1191–8.
55. Tosetti F, Vene R, Arena G, et al. N-(4-hydroxyphenyl)retinamide inhibits
retinoblastoma growth through reactive oxygen species-mediated cell death.
Mol Pharmacol 2003;63:565–73.
56. Simeone AM, Ekmekcioglu S, Broemeling LD, Grimm EA, Tari AM. A novel
mechanism by which N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell
growth: the production of nitric oxide. Mol Cancer Ther 2002;1:1009–17.
57. Simeone AM, Broemeling LD, Rosenblum J, Tari AM. HER2/neu reduces the
apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer
cells by decreasing nitric oxide production. Oncogene 2003;22:6739–47.
58. Maurer BJ, Melton L, Billups C, Cabot MC, Reynolds CP. Synergistic cytotoxicity in
solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators
of ceramide metabolism. J Natl Cancer Inst 2000;92:1897–909.
59. Umansky V, Ushmorov A, Ratter F, et al. Nitric oxide-mediated apoptosis in
human breast cancer cells requires changes in mitochondrial functions and is
independent of CD95 (APO-1/Fas). Int J Oncol 2000;16:109–17.
60. Hail N, Jr., Kim HJ, Lotan R. Mechanisms of fenretinide-induced apoptosis.
Apoptosis 2006;11:1677–94.
61. Veronesi U, Mariani L, Decensi A, et al. Fifteen-year results of a randomized
phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 2006;
17:1065–71.
62. Favoni RE, de Cupis A, Bruno S, et al. Modulation of the insulin-like growth
factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell
lines. Br J Cancer 1998;77:2138–47.
63. Fontana JA, Burrows-Mezu A, Clemmons DR, LeRoith D. Retinoid modulation of
insulin-like growth factor-binding proteins and inhibition of breast carcinoma
proliferation. Endocrinology 1991;128:1115–22.
64. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of
insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393–6.
65. Torrisi R, Parodi S, Fontana V, et al. Effect of fenretinide on plasma IGF-I and
IGFBP-3 in early breast cancer patients. Int J Cancer 1998;76:787–90.
66. Decensi A, Veronesi U, Miceli R, et al. Relationships between plasma insulin-
like growth factor-I and insulin-like growth factor binding protein-3 and second
breast cancer risk in a prevention trial of fenretinide. Clin Cancer Res 2003;9:
4722–9.
67. Simeone AM, Deng CX, Kelloff GJ, et al. N-(4-Hydroxyphenyl)retinamide is more
potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated
breast cancer cells. Carcinogenesis 2005;26:1000–7.
68. Brewer M, Kirkpatrick ND, Wharton JT, et al. 4-HPR modulates gene expression
in ovarian cells. Int J Cancer 2006;119:1005–13.
69. Bonanni B, Lazzeroni M, Veronesi U. Synthetic retinoid fenretinide in breast
cancer chemoprevention. Expert Rev Anticancer Ther 2007;7:423–32.
